Activin and Inhibin

BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.Form:SolidIC50&amp: Target:phosphodiesterase 9.

BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.Form:SolidIC50&amp: Target:phosphodiesterase 9.

BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.Form:SolidIC50&amp: Target:phosphodiesterase 9.

BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.Form:SolidIC50&amp: Target:phosphodiesterase 9.

BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.IC50&amp: Target:phosphodiesterase 9.

BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC 50 of 15.3 nM for human EP4-R . BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for

BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC 50 of 15.3 nM for human EP4-R . BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for

BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC 50 of 15.3 nM for human EP4-R . BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for

BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC 50 of 15.3 nM for human EP4-R . BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for

BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC 50 of 15.3 nM for human EP4-R . BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for

BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC 50 of 15.3 nM for human EP4-R . BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for

BAY-179 is a potent, selective, and species cross-reactive complex I inhibitor ( IC 50 =79 µM).Appearance:SolidBiological Activity:BAY-179 is a potent, selective, and species cross-reactive complex I inhibitor ( IC 50 =79 µM).